Resumen de acción RGT Argent BioPharma Limited, empresa multidisciplinar de desarrollo de fármacos, se dedica al suministro de medicamentos dirigidos a la inmunología y la neurología en todo el mundo. Saber más
Análisis de riesgos + 2 riesgos adicionales
Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de Argent BioPharma Limited Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del Argent BioPharma Precios históricos de las acciones Precio actual de la acción AU$0.17 Máximo en las últimas 52 semanas AU$0.55 Mínimo de 52 semanas AU$0.16 Beta 1.15 Cambio en 1 mes -35.85% Variación en 3 meses -65.66% Cambio de 1 año n/a Variación en 3 años -99.61% Variación en 5 años -99.54% Variación desde la OPV -99.35%
Noticias y actualizaciones recientes Argent BioPharma Limited has completed a Follow-on Equity Offering in the amount of AUD 7.2 million.
Argent Biopharma Limited Appoints Daniel Robinson as Director Nov 28 Argent BioPharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.2 million. Oct 28
Argent BioPharma Limited has filed a Follow-on Equity Offering in the amount of AUD 0.2 million. Oct 24
Co-Founder recently bought AU$1.6m worth of stock Oct 16
Full year 2024 earnings released: AU$0.47 loss per share (vs AU$7.07 loss in FY 2023) Oct 04 Ver más actualizaciones Argent BioPharma Limited has completed a Follow-on Equity Offering in the amount of AUD 7.2 million.
Argent Biopharma Limited Appoints Daniel Robinson as Director Nov 28 Argent BioPharma Limited has completed a Follow-on Equity Offering in the amount of AUD 0.2 million. Oct 28
Argent BioPharma Limited has filed a Follow-on Equity Offering in the amount of AUD 0.2 million. Oct 24
Co-Founder recently bought AU$1.6m worth of stock Oct 16
Full year 2024 earnings released: AU$0.47 loss per share (vs AU$7.07 loss in FY 2023) Oct 04
Less than half of directors are independent Oct 03
Argent BioPharma Limited, Annual General Meeting, Nov 28, 2024 Sep 25
Argent BioPharma Provides Update on Proposed Delisting from the Australian Securities Exchange Sep 24
Argent BioPharma Provides Update on Proposed Delisting from the Australian Securities Exchange Sep 23
Full year 2024 earnings released: AU$0.47 loss per share (vs AU$7.07 loss in FY 2023) Aug 31 Argent BioPharma Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.
New major risk - Market cap size Jun 04
Less than half of directors are independent May 27
Argent Biopharma Limited Announces the Appointment of Mr. Igor Bluvstein as Chief Financial Officer May 08
Argent BioPharma Limited Announces Appointment of Shlomo Sadoun to the Advisory Board Apr 16
Less than half of directors are independent Apr 10
Less than half of directors are independent Feb 16
New major risk - Market cap size Jan 24
Less than half of directors are independent Jan 12 MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 0.74 million. Jan 10
MGC Pharmaceuticals Limited's Product Artemic Receives FDA Approval in Saudi Arabia Dec 19
Less than half of directors are independent Dec 13
MGC Pharmaceuticals Limited Announces Board Changes Dec 01 MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of AUD 12.4 million. Nov 08
MGC Pharmaceuticals Limited, Annual General Meeting, Nov 30, 2023 Oct 09
Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.008 loss in FY 2022) Oct 05
New major risk - Shareholder dilution Sep 08
Full year 2023 earnings released: AU$0.007 loss per share (vs AU$0.008 loss in FY 2022) Sep 01
New minor risk - Financial data availability Aug 31
MGC Pharmaceuticals Limited Announces Positive Pre-Clinical Trial Results on CimetrA® Aug 15
MGC Pharmaceuticals Limited Announces Executive Changes Jul 30
MGC Pharmaceuticals Limited Announces Resignation of Arron Canicais, Joint Company Secretary Jul 29
New major risk - Shareholder dilution Jul 24 MGC Pharmaceuticals Limited has completed a Follow-on Equity Offering in the amount of £0.65 million. Jul 15
New major risk - Market cap size Jul 05 MGC Pharmaceuticals Limited Announces Appointment of Layton Mills as Non-Executive Director
MGC Pharmaceuticals Limited Announces Board Changes, Effective 1 June 2023 May 30
First half 2023 earnings released: AU$0.004 loss per share (vs AU$0.003 loss in 1H 2022) Mar 03
MGC Pharmaceuticals Limited Announces Change of CFO Feb 03
MGC Pharmaceuticals Ltd Completes the Pre-Clinical Rodent Studies on Cimetratm Jan 10
Less than half of directors are independent Jan 10
MGC Pharmaceuticals Limited Announces Resignation of Evan Hayes as Director Jan 03
MGC Pharmaceuticals Limited Announces Completion of CimetrA Efficacy Pre-Clinical Trial Dec 09
Mgc Pharmaceuticals Ltd Announces the Results of the Open Label Clinical Study, a White Label Version of ArtemiCTM Support Oct 25
MGC Pharmaceuticals Limited Provides an Update on Its Operations Oct 20
MGC Pharmaceuticals Limited, Annual General Meeting, Nov 24, 2022 Oct 18
Mgc Pharmaceuticals Limited Announces Board Changes Oct 05
Full year 2022 earnings released: AU$0.008 loss per share (vs AU$0.008 loss in FY 2021) Oct 05
MGC Pharmaceuticals Successfully Developed Herbal-Inspired Products for Treatment of Long Covid and Covid-19 Sep 23
MGC Pharmaceuticals Limited Announces Interim Results from the Data Collected from the Initial 16 Patients Participating in the CimetrA Dose Finding Study Sep 21
MGC Pharmaceuticals Limited, Annual General Meeting, Oct 05, 2022 Sep 05
Full year 2022 earnings released: AU$0.007 loss per share (vs AU$0.008 loss in FY 2021) Sep 03
MGC Pharmaceuticals Ltd Provides the Following Results from A Recently Completed Randomised, Double Blind, Placebo Controlled Study Investigating the Effect of MGC's Pharma's Epilepsy Treatment, Cannepil®, on Vehicle Driving Performance, Sedation and Mood (Trial) Aug 15 MGC Pharmaceuticals Limited announced that it expects to receive AUD 10 million in funding from Mercer Street Capital Partners, LLC Jul 30
Mgc Pharmaceuticals Ltd Announces Appointment of Mr. Robert Clements as Chief Commercial Officer Jul 19
MGC Pharmaceuticals Limited Announces Long COVID Study Results for Artemic Support Jul 15
MGC Pharmaceuticals Limited Receives Approval Granted for the Dose Finding Study of CimetrA on Patients Diagnosed With Covid-19 Jul 08
MGC Pharmaceuticals Limited Announces the Launch of ZAM- Medical Data App in Collaboration with Caba Tech Jul 06
MGC Pharmaceuticals Limited Announces CimetrA Pre-Clinical Trial Progress Report Jun 28
Mgc Pharmaceuticals Limited Announces Cimetra Clinical Trial Progress Jun 24
MGC Pharmaceuticals Ltd Has Completes Successful In-Vitro Preclinical Research Study into the Use of Cannabinoids to Treat Glioblastoma Multiforme Cells, A Fast-Growing and Aggressive Form of Brain Cancer Jun 16
Mgc Pharmaceuticals Ltd to Provide Details of the Results of Its Phase II Clinical Trial into the Effect of Its Proprietary Investigational Medicinal Product, CogniCann Jun 06
MGC Pharmaceuticals Ltd Patent Application forCannEpil®Drug Delivery System Patent granted by European IP Office May 12
Mgc Pharmaceuticals Limited Announces Appointment of Angela-Marie Graham as Its New London Based Chief Financial Officer Apr 26
MGC Pharmaceuticals Ltd Announces Patent Application for CimetrATM Approve by European IP Office Apr 21
MGC Pharmaceuticals Limited Announces Executive Changes Apr 12
MGC Pharmaceuticals Ltd Receives an Import Approval Permit for the Importation of ArtemiCTM Rescue into India Jan 07
Swiss PharmaCan Ag Announces Start of Clinical Trial with Glow LifeTech and MGC Pharmaceuticals to Confirm Treatment Potential of Artemic Support in Long Covid Patients Dec 22
MGC Pharmaceuticals Limited announced that it has received £5.5 million in funding Dec 02
MGC Pharmaceuticals Limited announced that it expects to receive AUD 10.3 million in funding Dec 01
Full year 2021 earnings released: AU$0.008 loss per share (vs AU$0.014 loss in FY 2020) Oct 04 Rentabilidad de los accionistas RGT AU Pharmaceuticals Mercado AU 7D -35.8% 0.5% 2.1% 1Y n/a -6.1% 10.3%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: Datos insuficientes para calcular los resultados de RGT en comparación con la industria Australian Pharmaceuticals.
Rentabilidad vs. Mercado: Datos insuficientes para determinar el rendimiento de RGT frente al mercado Australian.
Volatilidad de los precios Is RGT's price volatile compared to industry and market? RGT volatility RGT Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 10.1% Market Average Movement 7.9% 10% most volatile stocks in AU Market 16.3% 10% least volatile stocks in AU Market 3.0%
Precio estable de las acciones: El precio de las acciones de RGT ha sido volátil durante los últimos 3 meses en comparación con el mercado Australian.
Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de RGT en el último año.
Acerca de la empresa Argent BioPharma Limited, empresa multidisciplinar dedicada al desarrollo de fármacos, se dedica al suministro de medicamentos dirigidos a la inmunología y la neurología en todo el mundo. Entre sus principales productos candidatos figuran CimetrA, en fase IIB de ensayo clínico para el tratamiento de lesiones pulmonares agudas y SDRA; CannEpil, en fase I de ensayo clínico para la epilepsia refractaria; y CogniCann, en fase IIA de ensayo clínico para el alivio sintomático de la demencia y el Alzheimer. También participa en el desarrollo preclínico de Irnican para el tratamiento del glioblastoma multiforme; y RGAI03MW01, centrado en el tratamiento de heridas crónicas.
Mostrar más Resumen de fundamentos de Argent BioPharma Limited ¿Cómo se comparan los beneficios e ingresos de Argent BioPharma con su capitalización de mercado? Estadísticas fundamentales de RGT Capitalización bursátil AU$13.57m Beneficios(TTM ) -AU$17.53m Ingresos (TTM ) AU$891.08k
15.2x Ratio precio-ventas (PS)
-0.8x Ratio precio-beneficio (PE) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de RGT Ingresos AU$891.08k Coste de los ingresos AU$1.20m Beneficio bruto -AU$304.15k Otros gastos AU$17.23m Beneficios -AU$17.53m
Últimos beneficios comunicados
Jun 30, 2024
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) -0.32 Margen bruto -34.13% Margen de beneficio neto -1,967.34% Ratio deuda/patrimonio -149.0%
¿Cómo se ha desempeñado RGT a largo plazo?
Ver rendimiento histórico y comparativa
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2025/01/08 06:01 Precio de las acciones al final del día 2025/01/02 00:00 Beneficios 2024/06/30 Ingresos anuales 2024/06/30
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .
Fuentes analistas Argent BioPharma Limited está cubierta por 4 analistas. 0 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución Salvatore Gaetano Verdoliva Canaccord Genuity Robin Davison Capital Network by Proactive Investors Maxim Jacobs Edison Investment Research
Mostrar 1 más analistas 
